News — ROCKVILLE, MD (October 7, 2024) — A fluorescent dye could help scientists listen in on biochemical conversations between cartilage and bone during the earliest stages of osteoarthritis (OA)—even before the disease causes pain. The unexpected finding could someday lead to novel treatments for patients, according to research conducted on mice that was published today in FASEB BioAdvances.
OA is a painful condition in which the cartilage layer in a joint wears away, causing bone to rub against bone. This articular cartilage also becomes calcified, turning into bone. The progressive condition is common among people 60 years of age or older, as well as those with certain metabolic diseases or who place repetitive stress on a particular joint. Although there is no cure, early interventions could help prevent further damage. However, it is difficult to detect OA in early stages before a patient feels pain.
Bin Wang and colleagues at the Sidney Kimmel Medical College of Thomas Jefferson University wanted to know whether articular cartilage becomes calcified early in OA, so they studied a mouse model in which the right knee exhibits symptoms similar to the human disease.
A fluorescent red dye called alizarin complexone binds calcium-containing crystals, and the researchers injected this dye into both knees. Surprisingly, there was no fluorescence staining on the surface of the articular cartilage layer—where the team expected to find new calcification—in early OA stages.
The tidemark area, a barrier between the articular cartilage and a layer of calcified cartilage that resides on the bone was stained in both knees. “But we found more of the alizarin dye in the calcified cartilage and subchondral bone in osteoarthritic mice compared to control,” says Wang. Increased diffusion of the dye suggests that the early-OA knee joint is more permeable than the control.
With an injection, dye first goes directly into the synovial fluid that cushions the joints. In additional experiments, the researchers found that the dye could then move throughout the joint via three expected pathways. However, they also observed a fourth, brand-new pathway into the blood vessels in the outer covering of the bone, called the periosteum, via the tidemark. The fluorescence signal was greater in the periosteum, as well as in the subchondral bone of early-OA mouse joints than in controls.
Taken together, the findings mean that “alizarin complexone is a new tool that can detect diffusion, or biochemical communication, from the articular cartilage to the calcified cartilage and subchondral bone,” says Wang. Compared to controls, diffusion is boosted in early stages of OA. With this tool in hand, researchers can now use it to better understand the progression of OA as a step toward developing new treatments. “This is just the beginning,” says Wang.
Funding: National Institutes of Health, Rheumatology Research Foundation
Read the full article, “,” published online in FASEB BioAdvances.
###
About FASEB BioAdvances
FASEB BioAdvances is an international, fully open-access journal that publishes high-quality biological and biomedical research. It emphasizes sound science, robust experimentation, and welcomes studies across a wide spectrum, including null findings and incremental advances. The journal covers topics from molecular biology to ecosystems, featuring research articles, reviews, and perspectives on key issues in academia and society. Committed to open dissemination, FASEB BioAdvances makes science accessible to all.
About FASEB
FASEB is comprised of 22 scientific member societies with 110,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB’s mission is to advance health and well-being by promoting research and education in biological and biomedical sciences through collaborative advocacy and service to member societies and their members. Visit for more information.
Find FASEB Online
Website:
X:
LinkedIn:
Instagram:
RSS